期刊文献+

基于免疫分选的T淋巴细胞亚群嵌合性定量分析 被引量:1

Quantitative chimerism analysis of T lymphocyte subsets based on immune sorting
原文传递
导出
摘要 目的:建立基于免疫分选的T淋巴细胞亚群嵌合性定量分析的方法。方法:以淋巴细胞不同比例混合制备14组人工嵌合体血样,以免疫磁珠阳性选择法获取CD4+和CD8+T细胞亚群,分选后的细胞再进行16位点的短串重复序列(STR)多态性分析。结果:分选后T细胞亚群提取的DNA量能满足STR检测要求,当嵌合体中受体比例≥10%时,16个STR位点均能检出受体和供体特异性等位基因,按照STR峰面积计算的受体比例与理论值相符;当受体比例≤1%时,仅有部分位点能检出受体特异性等位基因,实测嵌合率与理论值存在差异。结论:建立了基于免疫分选的T细胞亚群嵌合性定量分析方法,可用于造血干细胞移植术后嵌合体监测。 Objective:To establish a quantitative method for chimerism analysis of T lymphocyte subsets based on immune sorting.Methods: 14 artificial chimera groups were mixed according to different lymphocytes proportion.The CD4+ and CD8+ T cell subsets were sorted by positive selection of immunomagnetic beads,and then were analyzed by STR polymorphisms technique.Results: The DNAs extracted from sorted T cells were fit for STR detection.All STR alleles specific for recipient or donor can be detected and the quantitative results were consistent with theoretic values in over 10% recipient chimeras.But only partial recipient alleles can be detected and the quantitative results were different from theoretic values in less then 1% recipient chimeras.Conclusion: A quantitative chimerism analysis of T cell subsets based on immune sorting was established.The method can be used to monitoring of hematopoietic chimerism following hematopoietic stem cell transplantation.
出处 《中国卫生检验杂志》 CAS 2011年第1期101-102,105,共3页 Chinese Journal of Health Laboratory Technology
基金 浙江省医卫科研基金(2008A036) 浙江省医卫青年人才基金(2008QN008)
关键词 嵌合体 免疫分选 造血干细胞移植 Chimera Immune sorting Hematopoietic stem cell transplantation
  • 相关文献

参考文献6

二级参考文献29

  • 1韩伟,陆道培,黄晓军,刘开彦,陈欢,许兰平,刘代红,江倩,陈育红,路瑾,王静波,吴彤,董陆佳,任汉云.HLA配型不合造血干细胞移植GIAC方案100例临床分析[J].中华血液学杂志,2004,25(8):453-457. 被引量:68
  • 2秦亚溱,阮国瑞,刘艳荣,李金兰,付家瑜,王卉,常艳,江滨,江倩,江浩,丘镜滢,陈珊珊,陆道培.实时定量RT-PCR监测慢性粒细胞白血病患者伊马替尼治疗过程中bcr/abl mRNA水平[J].中华血液学杂志,2005,26(1):1-5. 被引量:12
  • 3陈育红,黄晓军,陈欢,许兰平,刘代红,江倩,张耀臣,韩伟,高志勇,王景枝,刘开彦,吴彤,陆道培.非血缘关系异基因造血干细胞移植66例分析[J].中华血液学杂志,2005,26(11):656-660. 被引量:19
  • 4秦亚溱,李金兰,主鸿鹄,阮国瑞,李玲娣,张艳,许兰平,刘代红,黄晓军,陈珊珊,陆道培,刘艳荣.实时定量RT-PCR监测慢性粒细胞白血病患者造血干细胞移植后bcr-abl mRNA水平[J].中华血液学杂志,2006,27(8):511-514. 被引量:19
  • 5Goldman JM, Hughes T, Radich J . Continuing reduction in level of residual disease after 4 year in patients with CML in chronic phase responding to first-line imatinib in the IRIS study. Blood, 2005,106:51a.
  • 6Simonsson B. Beneficial ffects of cytogenetic and molecular response on long term outcome in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib (IM) : update from the IRIS study. The IRIS study group. Blood, 2005, 106:52a.
  • 7Savage DG, Goldman JM. Allografting for chronic myeloid leukemia. Curr Opin Hematol, 1997,4:369-376.
  • 8Gratwohl A, Hermans J, Niederwieser D, et al. Bone marrow transplantation for chronic myeloid leukemia: long-term results. Chronic Leukemia Working Party of the European Group for Bone Marrow Transplantation. Bone Marrow Transplant, 1993,12:509- 516.
  • 9Horowitz MM, Rowlings PA, Passweg JR. Allogeneic bone marrow transplantation for CML: a report from the International Bone Marrow Transplant Registry. Bone Marrow Transplant, 1996,17: S5- S6.
  • 10Slavin S, Naparstek E, Nagler A, et al. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood, 1996, 87:2195-2204.

共引文献46

同被引文献10

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部